Empagliflozin ameliorated the RNA expression of inflammatory factors in PVAT, attenuated diabetes-induced endothelial dysfunction, and decreased the atherosclerotic lesion area in the aortic arch of diabetic ApoE–/– mice (Ganbaatar et al., 2020). Here, APOE is linked to endothelial dysfunction.